US Markets
Home›US Markets›Equities›Eli Lilly blows past estimates, hikes sales outlook as…
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
← Newer storyGet to Know the Broker: Matt Ellingson of Sotheby’s International Rea…Older story →USD/CHF Price Forecast: US Dollar maintains its constructive bias whi…
More like this
US MarketsAlphabet Stumbles, U.S. Economy Surges